Syntara (ASX:SNT) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Syntara FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Syntara's Free Cash Flow for the six months ended in Dec. 2023 was A$-4.85 Mil. Syntara's Revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Therefore, Syntara's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Syntara's current FCF Yield % is -38.92%.

The historical rank and industry rank for Syntara's FCF Margin % or its related term are showing as below:

ASX:SNT' s FCF Margin % Range Over the Past 10 Years
Min: -565.51 Med: -124.47 Max: 155.45
Current: -248.71

During the past 13 years, the highest FCF Margin % of Syntara was 155.45%. The lowest was -565.51%. And the median was -124.47%.

ASX:SNT's FCF Margin % is ranked worse than
91.99% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 0.245 vs ASX:SNT: -248.71

Syntara FCF Margin % Historical Data

The historical data trend for Syntara's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara FCF Margin % Chart

Syntara Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

-366.09

-197.21

36.30

-220.97

-128.62

Syntara Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-103.71	-637.91	-87.12	-140.48	-

Competitive Comparison of Syntara's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syntara's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syntara's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Syntara's FCF Margin % falls into.

Syntara FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Syntara's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-7.415	/	5.765
	=	-128.62 %

Syntara's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.853	/	0
	=	%

Syntara FCF Margin % Related Terms

Thank you for viewing the detailed overview of Syntara's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Syntara (ASX:SNT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

UUDA:Germany

Address

20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086

Website

https://www.pharmaxis.com.au

Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.